119 related articles for article (PubMed ID: 38266804)
21. Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.
de Groot AF; Blok EJ; Charehbili A; Engels CC; Smit VTHBM; Dekker-Ensink NG; Putter H; Meershoek-Klein Kranenbarg E; van de Velde CJH; Liefers GJ; Nortier JWR; Kuppen PJK; van der Burg SH; Kroep JR
Breast Cancer Res Treat; 2019 Jun; 175(3):605-615. PubMed ID: 30868392
[TBL] [Abstract][Full Text] [Related]
22. Chemosensitivity, tumor infiltrating lymphocytes (TILs), and survival of postpartum PABC patients treated by neoadjuvant chemotherapy.
Labrosse J; Abdennebi I; Thibault L; Laas E; Merckelbagh H; Morel C; Lam T; Lae M; Reyal F; Hamy AS
Breast; 2018 Dec; 42():61-67. PubMed ID: 30179779
[TBL] [Abstract][Full Text] [Related]
23. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer.
Bassez A; Vos H; Van Dyck L; Floris G; Arijs I; Desmedt C; Boeckx B; Vanden Bempt M; Nevelsteen I; Lambein K; Punie K; Neven P; Garg AD; Wildiers H; Qian J; Smeets A; Lambrechts D
Nat Med; 2021 May; 27(5):820-832. PubMed ID: 33958794
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant Endocrine Therapy: A Potential Way to Make Cold Hormone Receptor-Rich Breast Cancer Hot.
Wu Y; Gong X; Wang K; Yu C; Qiu J; Zhang S; Hu Y; Hu K
Comb Chem High Throughput Screen; 2023; 26(5):1030-1041. PubMed ID: 35718967
[TBL] [Abstract][Full Text] [Related]
25. The immune microenvironment characterisation and dynamics in hormone receptor-positive breast cancer before and after neoadjuvant endocrine therapy.
Oner G; Broeckx G; Van Berckelaer C; Zwaenepoel K; Altintas S; Canturk Z; Tjalma W; Berneman Z; Peeters M; Pauwels P; van Dam PA
Cancer Med; 2023 Sep; 12(17):17901-17913. PubMed ID: 37553911
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma.
Böhm S; Montfort A; Pearce OM; Topping J; Chakravarty P; Everitt GL; Clear A; McDermott JR; Ennis D; Dowe T; Fitzpatrick A; Brockbank EC; Lawrence AC; Jeyarajah A; Faruqi AZ; McNeish IA; Singh N; Lockley M; Balkwill FR
Clin Cancer Res; 2016 Jun; 22(12):3025-36. PubMed ID: 27306793
[TBL] [Abstract][Full Text] [Related]
27. Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers.
Gazinska P; Milton C; Iacovacci J; Ward J; Buus R; Alaguthurai T; Graham R; Akarca A; Lips E; Naidoo K; Wesseling J; Marafioti T; Cheang M; Gillett C; Wu Y; Khan A; Melcher A; Salgado R; Dowsett M; Tutt A; Roxanis I; Haider S; Irshad S
Clin Cancer Res; 2022 Oct; 28(20):4494-4508. PubMed ID: 36161312
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant Chemotherapy Use for Nonmetastatic Breast Cancer at Five Public South African Hospitals and Impact on Time to Initial Cancer Therapy.
O'Neil DS; Nietz S; Buccimazza I; Singh U; Čačala S; Stopforth LW; Joffe M; Jacobson JS; Neugut AI; Crew KD; Ruff P; Cubasch H
Oncologist; 2019 Jul; 24(7):933-944. PubMed ID: 30518615
[TBL] [Abstract][Full Text] [Related]
29. Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy.
Chic N; Schettini F; Brasó-Maristany F; Sanfeliu E; Adamo B; Vidal M; Martínez D; Galván P; González-Farré B; Cortés J; Gavilá J; Saura C; Oliveira M; Pernas S; Martínez-Sáez O; Soberino J; Ciruelos E; Carey LA; Muñoz M; Perou CM; Pascual T; Bellet M; Prat A
EBioMedicine; 2021 Jul; 69():103451. PubMed ID: 34161883
[TBL] [Abstract][Full Text] [Related]
30. Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
Muraro E; Comaro E; Talamini R; Turchet E; Miolo G; Scalone S; Militello L; Lombardi D; Spazzapan S; Perin T; Massarut S; Crivellari D; Dolcetti R; Martorelli D
J Transl Med; 2015 Jun; 13():204. PubMed ID: 26116238
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant chemotherapy is linked to an amended anti-tumorigenic microenvironment in gastric cancer.
Huan X; Zou K; Zhang P; Ding H; Luo C; Xiang C; Xu S; Zhuang Y; Wu C; Wang Y; Wu X; Chen C; Zhang J; Yao X; Liu F; Liu S; Wu Z
Int Immunopharmacol; 2024 Jan; 127():111352. PubMed ID: 38091833
[TBL] [Abstract][Full Text] [Related]
32. Predictive value of stromal tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant chemotherapy: A meta-analysis.
Xia G; Zhang Z; Jiang Q; Wang H; Wang J
Medicine (Baltimore); 2024 Feb; 103(6):e36810. PubMed ID: 38335394
[TBL] [Abstract][Full Text] [Related]
33. Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer.
Kaewkangsadan V; Verma C; Eremin JM; Cowley G; Ilyas M; Eremin O
J Immunol Res; 2016; 2016():4757405. PubMed ID: 27777963
[TBL] [Abstract][Full Text] [Related]
34. A high interferon gamma signature of CD8
Li S; Li K; Tian F; Li H; Xia Q; Li T; Dong B; Li D; Yu J; Zhang J; Wang L; Zhang C; Xu S; Zhao Y; Liu Y
Front Immunol; 2022; 13():1056144. PubMed ID: 36685525
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Yang X; Rao J; Yang W; Shui R
Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
[TBL] [Abstract][Full Text] [Related]
37. X-box binding protein 1 (XBP1): a potential role in chemotherapy response, clinical pathologic features, non-inflamed tumour microenvironment for breast cancer.
Zhu Z; Zhan H; Sun A; Huang H; Chen B; Zhang F
Biosci Rep; 2022 Jun; 42(6):. PubMed ID: 35543228
[TBL] [Abstract][Full Text] [Related]
38. Neo-peripheral adaptive immune score predicts neoadjuvant chemotherapy for locally advanced breast cancer.
Wang H; Sheng X; Yan T; Xu Y; Wang Y; Lin Y; Zhang J; Ye Y; Xu S; Zhou L; Yin W; Lu J
Breast Cancer Res Treat; 2023 Jan; 197(2):343-354. PubMed ID: 36409395
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC.
Gaudreau PO; Negrao MV; Mitchell KG; Reuben A; Corsini EM; Li J; Karpinets TV; Wang Q; Diao L; Wang J; Federico L; Parra-Cuentas ER; Khairullah R; Behrens C; Correa AM; Gomez D; Little L; Gumbs C; Kadara HN; Fujimoto J; McGrail DJ; Vaporciyan AA; Swisher SG; Walsh G; Antonoff MB; Weissferdt A; Tran H; Roarty E; Haymaker C; Bernatchez C; Zhang J; Futreal PA; Wistuba II; Cascone T; Heymach JV; Sepesi B; Zhang J; Gibbons DL
J Thorac Oncol; 2021 Jan; 16(1):127-139. PubMed ID: 33096269
[TBL] [Abstract][Full Text] [Related]
40. Immune correlates of the differing pathological and therapeutic effects of neoadjuvant chemotherapy in breast cancer.
Kim R; Kawai A; Wakisaka M; Sawada S; Shimoyama M; Yasuda N; Hidaka M; Morita Y; Ohtani S; Arihiro K
Eur J Surg Oncol; 2020 Jan; 46(1):77-84. PubMed ID: 31563296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
